CASTLE BIOSCIENCES INC

NASDAQ: CSTL (Castle Biosciences, Inc.)

Last update: 28 Aug, 2:06AM

29.44

0.59 (2.05%)

Market Trend

Short Term Medium Term
Industry Diagnostics & Research (US) Mixed Mixed
Diagnostics & Research (Global) Mixed Mixed
Stock Castle Biosciences, Inc. Mixed Bullish

Stockmoo Score

-0.3

Similar Stocks

Stock Market Cap DY P/E P/B
CSTL 817 M - - 2.04
EXAS 9 B - - 3.90
RDNT 5 B - 357.78 5.69
VCYT 2 B - - 2.23
CDNA 939 M - - 5.67
BIAF 23 M - - 5.82

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Sector Healthcare
Industry Diagnostics & Research
Investment Style Small Growth
52 Weeks Range
12.07 (-59%) — 30.46 (3%)
Median 34.00 (15.49%)
Total 1 Buy
Firm Date Target Price Call Price @ Call
Baird 05 Jul 2024 34.00 (15.49%) Buy 17.40
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BRADBURY DANIEL - 29.48 -7,867 -231,919
MAETZOLD DEREK J - 29.61 -7,116 -212,657
OELSCHLAGER KRISTEN M - 29.18 -5,832 -170,178
Aggregate Net Quantity -20,815
Aggregate Net Value ($) -614,754
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 29.56
Name Holder Date Type Quantity Price Value ($)
MAETZOLD DEREK J Officer 11 Sep 2024 Automatic sell (-) 996 31.03 30,906
MAETZOLD DEREK J Officer 11 Sep 2024 Automatic sell (-) 1,620 31.03 50,269
MAETZOLD DEREK J Officer 09 Sep 2024 Automatic sell (-) 996 29.33 29,213
MAETZOLD DEREK J Officer 09 Sep 2024 Automatic sell (-) 1,590 29.33 46,635
BRADBURY DANIEL Director 05 Sep 2024 Automatic sell (-) 7,867 29.48 231,919
MAETZOLD DEREK J Officer 04 Sep 2024 Automatic sell (-) 298 28.91 8,615
MAETZOLD DEREK J Officer 04 Sep 2024 Automatic sell (-) 500 28.91 14,455
OELSCHLAGER KRISTEN M Officer 03 Sep 2024 Automatic sell (-) 5,832 29.18 170,178
MAETZOLD DEREK J Officer 03 Sep 2024 Automatic sell (-) 417 29.18 12,168
MAETZOLD DEREK J Officer 03 Sep 2024 Automatic sell (-) 699 29.18 20,397
Date Type Details
16 Sep 2024 Announcement Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
11 Sep 2024 Announcement DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
05 Sep 2024 Announcement Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
28 Aug 2024 Announcement Castle Biosciences to Participate in Upcoming Investor Conferences
05 Aug 2024 Announcement Castle Biosciences Reports Second Quarter 2024 Results
30 Jul 2024 Announcement Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
22 Jul 2024 Announcement Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
15 Jul 2024 Announcement Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
11 Jul 2024 Announcement Castle Biosciences Honored with Top Workplaces Awards
24 Jun 2024 Announcement Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
20 Jun 2024 Announcement Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria